EnteraBio News and Activities

EnteraBio is owned by Elbit Systems.

Elbit Systems is one of the...

• Forbes Global 2000 (#1947);
• TOB Iconic 10,000.

Elbit Systems is a company listed under the stock ticker ESLT (IL).

Elbit Systems has a direct presence in 2 countries.

Elbit Systems has 3 subsidiaries including Cyberbit, Elbit Systems of America and EnteraBio.

They are in:

• Defense & Space50%
• IT Security25%
• Other25%

View the org chart displaying its 13 main executives

Most searched biographies at EnteraBio

• Miranda Toledano, Chief Executive Officer
• Sean Ellis, Director
• Haya Taitel, Director

Create your alert
to follow the executive moves at EnteraBio.

Elbit Systems has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by EnteraBio

• Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development | Entera Bio Ltd.
• Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting | Entera Bio Ltd.
• Entera Bio to Participate in Upcoming Investor Conferences | Entera Bio Ltd.
• Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
• Entera Bio Announces Q2 2023 Financial Results and Corporate Updates | Entera Bio Ltd.
• Press Releases | Entera Bio Ltd.
• Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
• Press Releases | Entera Bio Ltd.
• אחסון וורדפרס מנוהל - uPress
• Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors | Entera Bio Ltd.
• View more press releases Close

Social media about EnteraBio

• EnteraBio on Wikipedia, Google News & Yahoo Finance
• EnteraBio on LinkedIn, X (Twitter) & YouTube